Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a special PET scan outperform MRI for spotting brain tumors?

NCT ID NCT04890028

Diagnosis Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET method could improve detection and help guide future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

Dec 2021

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primitive cancer (brest cancer, lung cancer, melanoma) proven histologically * Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm * Age \> 18 years * Patient has valid health insurance * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations Exclusion Criteria: * History of irradiation cerebral * History of brain surgery for brain metastasis or glial tumor * Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the realization of DOPA PET/CT, * New anti-tumor treatment started between the discovery of brain metastases and the performance of DOPA PET/CT * Other concomitant cancer, or history of cancer in the 5 years preceding the performance of DOPA PET/CT * Pregnant or lactating females * Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian. Disorder precluding understanding of trial information or informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm lung cancer lung neoplasm melanoma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases MRI

Contacts and locations

Locations

  • CHU Angers

    Angers, 49055, France

  • Institut de Cancerologie de L'Ouest

    Saint-Herblain, 44055, France

  • Institut de Cancerologie de l'Ouest

    Angers, 49055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.